Daiichi Sankyo Co. Ltd. Press Release

Title Picture
10/31/2018 - 05:22
Daiichi Sankyo Announces Discontinuation of Intradermal Seasonal Influenza Vaccine Development in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
10/31/2018 - 04:48
Announcement for partnership termination of sales and information provision of lyophilized hemophilus influenza type b vaccine ActHIB in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
10/18/2018 - 16:28
Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo's picture
Daiichi Sankyo
10/17/2018 - 05:38
Daiichi Sankyo Submits Application in Japan for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Daiichi Sankyo's picture
Daiichi Sankyo
10/12/2018 - 09:12
Filing of Lawsuit on Patent Infringement Concerning Herceptin Injection, and a Petition for Provisional Disposition Order (1)
Chugai's picture
Chugai
10/09/2018 - 00:22
Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Announce Second Public Recruitment Offering of "JOINUS", a Joint Research Program to Discover New Drugs using Drug-Repositioning Compound Library
Daiichi Sankyo's picture
Daiichi Sankyo
10/02/2018 - 22:33
Japan MHLW Grants Orphan Drug Designation to Axicabtagene Ciloleucel for Treatment of Certain Types of B-Cell Lymphoma
Daiichi Sankyo's picture
Daiichi Sankyo
09/11/2018 - 18:19
Daiichi Sankyos FLT3 Inhibitor Quizartinib Receives Orphan Drug Designation from Japanese MHLW for FLT3-Mutated AML
Daiichi Sankyo's picture
Daiichi Sankyo
09/05/2018 - 19:42
Vaccines Market by Key Players Strategies and Market Segmentation | MarketsandMarketsResearchPvtLtd
MarketsandMarketsResearchPvtLtd's picture
MarketsandMarke...
08/01/2018 - 05:27
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyos FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Daiichi Sankyo's picture
Daiichi Sankyo
07/31/2018 - 07:59
Daiichi Sankyo Announces Split off (Simple Absorption-type Split) and Transfer of 41 Long-listed Products in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
07/31/2018 - 06:10
Daiichi Sankyo Announces Reversal of Tax-related Expenses in its Non-consolidated Financial Results (Japanese GAAP)
Daiichi Sankyo's picture
Daiichi Sankyo
07/30/2018 - 17:03
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Daiichi Sankyo's picture
Daiichi Sankyo
07/02/2018 - 17:04
Daiichi Sankyo Obtains Approval for Additional Indication and Dosage for Diagnogreen for Injection 25 mg in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
06/24/2018 - 02:39
Alirocumab and Statins Highly Effective in People with Diabetes with Acute Coronary Syndrome
American Diabetes Association's picture
American Diabet...
06/14/2018 - 22:09
Daiichi Sankyo Launches FENTANYL CITRATE TAPE for 1day DAIICHI SANKYO in Japan for Long-Acting Cancer Pain Relief
Daiichi Sankyo's picture
Daiichi Sankyo
05/31/2018 - 12:03
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer
Daiichi Sankyo's picture
Daiichi Sankyo
05/30/2018 - 12:18
Daiichi Sankyo U.S. subsidiary, Luitpold Pharmaceuticals, Inc., to Be Merged with Its Own Subsidiaries and Renamed
Daiichi Sankyo's picture
Daiichi Sankyo
05/30/2018 - 11:50
Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development
Daiichi Sankyo's picture
Daiichi Sankyo
05/15/2018 - 17:25
Daiichi Sankyo Launches Naruvein Injection for Cancer Pain Treatment in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
05/14/2018 - 19:25
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
Daiichi Sankyo's picture
Daiichi Sankyo
05/10/2018 - 21:44
Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board
Daiichi Sankyo's picture
Daiichi Sankyo
04/26/2018 - 23:43
Daiichi Sankyo to Reorganize Kitasato Daiichi Sankyo Vaccine into Specialized Manufacturing Subsidiary
Daiichi Sankyo's picture
Daiichi Sankyo
04/25/2018 - 00:43
Daiichi Sankyo Announces Phase 1/2 Clinical Trial Results for DS-5141 (Therapeutic Agent for Duchenne Muscular Dystrophy) in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
04/17/2018 - 20:37
AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium 10 mg and 20 mg Granules for Suspension, Sachet, in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
04/04/2018 - 21:27
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Initiative
Daiichi Sankyo's picture
Daiichi Sankyo
03/30/2018 - 00:57
Daiichi Sankyo Agrees to Modify the Terms of the Settlement Program for U.S. Olmesartan Products Liability Litigation
Daiichi Sankyo's picture
Daiichi Sankyo
03/26/2018 - 23:22
Daiichi Sankyos HER2-Targeting Antibody Drug Conjugate DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan MHLW
Daiichi Sankyo's picture
Daiichi Sankyo
03/23/2018 - 00:09
Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over
GlaxoSmithKline's picture
GlaxoSmithKline
03/07/2018 - 20:01
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
Daiichi Sankyo's picture
Daiichi Sankyo
02/26/2018 - 18:54
Daiichi Sankyo Announces NDA submission in Japan of Esaxerenone for Treatment of Hypertension
Daiichi Sankyo's picture
Daiichi Sankyo
02/26/2018 - 17:48
Daiichi Sankyo Reports Rupture of Liquid Storage Tank at Kitamoto Facility of Kitasato Daiichi Sankyo Vaccine
Daiichi Sankyo's picture
Daiichi Sankyo
02/22/2018 - 20:07
Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
Daiichi Sankyo's picture
Daiichi Sankyo
02/22/2018 - 18:36
Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018
Daiichi Sankyo's picture
Daiichi Sankyo
02/22/2018 - 00:15
Daiichi Sankyo Submits Application for Additional Indication and Dosage for Diagnogreen for Injection 25 mg in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
02/15/2018 - 01:23
Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
02/06/2018 - 17:48
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Daiichi Sankyo's picture
Daiichi Sankyo
02/01/2018 - 21:09
Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018
Daiichi Sankyo's picture
Daiichi Sankyo
02/01/2018 - 21:08
Daiichi Sankyo Announces Update on Amgen Inc.s Phase 3 Clinical Trial Evaluating Denosumab as Adjuvant Breast Cancer Treatment
Daiichi Sankyo's picture
Daiichi Sankyo
01/19/2018 - 02:52
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
Daiichi Sankyo's picture
Daiichi Sankyo
12/12/2017 - 20:49
Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
Daiichi Sankyo's picture
Daiichi Sankyo
12/12/2017 - 18:06
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
Daiichi Sankyo's picture
Daiichi Sankyo
12/07/2017 - 18:35
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium
Daiichi Sankyo's picture
Daiichi Sankyo
12/06/2017 - 21:54
Daiichi Sankyos Subsidiary Daiichi Sankyo Espha to Launch New Generic Drugs
Daiichi Sankyo's picture
Daiichi Sankyo
11/30/2017 - 20:39
Daiichi Sankyo and Translational Sciences Conclude Agreement, after Successful Phase 1a Trial, as Part of Daiichi Sankyo Portfolio Prioritization
Daiichi Sankyo's picture
Daiichi Sankyo
11/29/2017 - 23:33
Daiichi Sankyo to Absorb Japan Research Subsidiary, Asubio Pharma Co., Ltd.
Daiichi Sankyo's picture
Daiichi Sankyo
11/29/2017 - 21:07
Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary
Daiichi Sankyo's picture
Daiichi Sankyo
11/28/2017 - 22:11
Daiichi Sankyo Launches Anticoagulant Lixiana OD Tablets (orally disintegrating tablets) in Japan
Daiichi Sankyo's picture
Daiichi Sankyo
11/20/2017 - 22:44
Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer
Daiichi Sankyo's picture
Daiichi Sankyo
11/14/2017 - 19:46
New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017
Daiichi Sankyo's picture
Daiichi Sankyo
10/29/2017 - 23:18
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing
Daiichi Sankyo's picture
Daiichi Sankyo
10/15/2017 - 22:34
Commencement of Collaborative Research on Measurement of Exosomes in Blood from Cancer Patients
Daiichi Sankyo's picture
Daiichi Sankyo
10/10/2017 - 18:18
Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library
Daiichi Sankyo's picture
Daiichi Sankyo
09/29/2017 - 03:17
Daiichi Sankyo Underwrites All Shares Issued by Kitasato Daiichi Sankyo Vaccine
Daiichi Sankyo's picture
Daiichi Sankyo
09/25/2017 - 17:21
Daiichi Sankyo Announces TaNeDS Global 2018 Collaborative Drug Discovery Program
Daiichi Sankyo's picture
Daiichi Sankyo
09/24/2017 - 19:15
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Study in Japan of Esaxerenone for Treatment of Essential Hypertension
Daiichi Sankyo's picture
Daiichi Sankyo
09/14/2017 - 17:14
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
Daiichi Sankyo's picture
Daiichi Sankyo
09/11/2017 - 17:51
Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress
Daiichi Sankyo's picture
Daiichi Sankyo
09/06/2017 - 20:06
Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers
Daiichi Sankyo's picture
Daiichi Sankyo
09/06/2017 - 19:40
Japans First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent
Daiichi Sankyo's picture
Daiichi Sankyo